Featured Company News – Santhera Selected Veeva CRM and Veeva OpenData as Commercial Software and Data Platform

LONDON, UK / ACCESSWIRE / June 30, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Veeva Systems Inc. (NYSE: VEEV), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=VEEV. The Company announced on June 28, 2017, that Santhera Pharmaceuticals, a rare disease pharmaceutical Company, has selected Veeva CRM and Veeva OpenData as a commercial software and data platform for its first product launch. The Company will adopt Veeva Commercial Cloud Solutions to establish a consistent, global approach to commercialization. For immediate access to our complimentary reports, including today’s coverage, register for free now at: http://protraderdaily.com/register/.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on VEEV. Go directly to your stock of interest and access today’s free coverage at: http://protraderdaily.com/optin/?symbol=VEEV.

The Announcement

According to the Company, accurate customer data is the foundation for commercial excellence, and especially, with the growing number of stakeholders, robust and accurate data update turns to be of utmost importance. Veeva currently offers complete customer data and multichannel engagement to help life sciences organizations and pharmaceutical Companies enhance their interactions with healthcare professionals across the world.

The Company offers field team access to up-to-date customer reference data, where they need it most to enable faster and tailored interactions. When a particular user submits data change requests, it is properly verified and updated within hours, against the industry average of 10 or more days. Veeva recently announced that 100 customers have adopted Veeva OpenData, including Allergan, which like other firms, has moved to Veeva OpenData for more up-to-date and complete customer reference data.

Veeva stated that according to a recent survey, a majority of Companies struggle with customer data quality issues, where incorrect physician addresses, lack of information about the right doctor to contact, or outdated information about specialty and license status, creates a sense of frustration among the field employees, hence affecting the operational performance of the individuals. Accordingly, the Company stated that on the basis of its research, about 78% of the Companies have initiatives underway to enhance data quality within the next two years.

Veeva CRM Events Management

Last year, on December 12, 2016, the Company announced that Advanced Health Media (AHM), HealthSTAR Communications, MedForce, Physicians World, and Vector Health are leveraging the power of Veeva CRM Events Management to offer life sciences customers a full-fledged end-to-end solution for enterprise-wide planning and execution of live and virtual events. According to the Company, about 75% of organizations report that the use of disparate systems is the biggest issue in events management. Hence, in an attempt to minimize the burden, leading Companies are integrating and certifying their offerings with Veeva CRM Events Management, a single solution to plan and execute all events across the enterprise.

The Company

Veeva Systems is a leading cloud-based software provider for the global life sciences segment. The Company currently has about 525 customers under its portfolio, with offices in Europe, Asia, Latin America, and headquarters at San Francisco’s Bay Area. The Company’s Veeva OpenData service currently offers access to over 20 million HCPs and their HCO affiliations, coverings all specialties and classes of trade, spanning across 39 nations.

On May 08, 2017, Veeva Systems announced that Bristol-Myers Squibb, a global pharmaceutical firm, expanded its adoption of Veeva Commercial Cloud in key markets outside the United States. Veeva additionally confirmed that Bristol-Myers Squibb will add Veeva CRM Events Management to better manage field events by streamlining approvals and reducing the complexity of the process.

Last Close Stock Review

On Thursday, June 29, 2017, the stock closed the trading session at $61.36, falling 1.68% from its previous closing price of $62.41. A total volume of 1.26 million shares have exchanged hands. Veeva Systems’ stock price skyrocketed 20.67% in the last three months, 48.57% in the past six months, and 80.36% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have soared 50.76%. The stock is trading at a PE ratio of 93.11. At Thursday’s closing price, the stock’s net capitalization stands at $8.45 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 467203